title: A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma.
abstract: Clinical studies suggest that treatment with vaccines comprised of idiotype protein may be associated with improved clinical outcome in follicular lymphoma patients. The time-consuming process required to generate patient-specific vaccines is a major limitation, however. Here we report results of a pilot clinical trial with a novel autologous, tumor-derived proteoliposome vaccine formulation that could be rapidly produced within a single day. Vaccination was safe, induced autologous tumor-specific type 1 cytokine responses in 5 out of 10 follicular lymphoma patients, and was associated with induction of a sustained complete response in one patient. Other patients had large tumor burdens and progressed after a median duration of 8 months. These results suggest that further testing of this vaccine formulation, particularly in the setting of minimal disease, is warranted. Furthermore, the proteoliposome formulation may provide a model for vaccine development for other human cancers, for which tumor-associated antigens need not be defined.
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. sneelapu@mdanderson.org
authors.forename: Sattva S
authors.initials: SS
authors.lastname: Neelapu
authors.forename: Barry L
authors.initials: BL
authors.lastname: Gause
authors.forename: Linda
authors.initials: L
authors.lastname: Harvey
authors.forename: Seung-Tae
authors.initials: ST
authors.lastname: Lee
authors.forename: Andrea Robin
authors.initials: AR
authors.lastname: Frye
authors.forename: Jessie
authors.initials: J
authors.lastname: Horton
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Robb
authors.forename: Mircea C
authors.initials: MC
authors.lastname: Popescu
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kwak
mesh_terms: D000328:Adult; D019496:Cancer Vaccines / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D016207:Cytokines / Q000187:drug effects; D005260:Female; D006801:Humans; D007109:Immunity; D008224:Lymphoma, Follicular / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011510:Proteolipids / Q000627:therapeutic use*; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D019496:Cancer Vaccines; D016207:Cytokines; D011510:Proteolipids; C020485:proteoliposomes